Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBIT Margin (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of EBIT Margin data on record, last reported at 72028.1% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 6725984.0% year-over-year to 72028.1%; the TTM value through Dec 2025 reached 18599.81%, down 1582092.0%, while the annual FY2025 figure was 18599.81%, 1582092.0% down from the prior year.
  • EBIT Margin reached 72028.1% in Q4 2025 per CLDX's latest filing, down from 7361700.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 7361700.0% in Q3 2025 and bottomed at 72028.1% in Q4 2025.
  • Average EBIT Margin over 5 years is 358402.01%, with a median of 4063.08% recorded in 2023.
  • The widest YoY moves for EBIT Margin: up 736333353bps in 2025, down -6725984bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 10792.81% in 2021, then plummeted by -116bps to 1728.77% in 2022, then skyrocketed by 33bps to 1152.92% in 2023, then crashed by -314bps to 4768.26% in 2024, then tumbled by -1411bps to 72028.1% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 72028.1% in Q4 2025, 7361700.0% in Q3 2025, and 8747.53% in Q2 2025.